Mattsson N - Search Results

1

Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C.

Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Månsson JE, Porter FD, Blennow K. Mattsson N, et al. JIMD Rep. 2012;3:45-52. doi: 10.1007/8904_2011_47. Epub 2011 Sep 28. JIMD Rep. 2012. PMID: 23430872 Free PMC article.

2

Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study.

Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Månsson JE, Porter FD, Blennow K. Mattsson N, et al. Neurology. 2011 Jan 25;76(4):366-72. doi: 10.1212/WNL.0b013e318208f4ab. Epub 2010 Dec 29. Neurology. 2011. PMID: 21205675 Free PMC article.

3

Cerebrospinal fluid biomarkers of β-amyloid metabolism and neuronal damage in epileptic seizures.

Shahim P, Rejdak R, Ksiazek P, Blennow K, Zetterberg H, Mattsson N, Rejdak K. Shahim P, et al. Among authors: mattsson n. Eur J Neurol. 2014 Mar;21(3):486-91. doi: 10.1111/ene.12336. Epub 2013 Dec 26. Eur J Neurol. 2014. PMID: 24372994

4

Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients.

Mattsson N, Haghighi S, Andersen O, Yao Y, Rosengren L, Blennow K, Praticò D, Zetterberg H. Mattsson N, et al. Neurosci Lett. 2007 Mar 13;414(3):233-6. doi: 10.1016/j.neulet.2006.12.044. Epub 2006 Dec 30. Neurosci Lett. 2007. PMID: 17227694

5

Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis.

Mattsson N, Rüetschi U, Podust VN, Stridsberg M, Li S, Andersen O, Haghighi S, Blennow K, Zetterberg H. Mattsson N, et al. J Neurochem. 2007 Dec;103(5):1932-9. doi: 10.1111/j.1471-4159.2007.04985.x. Epub 2007 Oct 22. J Neurochem. 2007. PMID: 17953655 Free article.

6

CSF biomarkers: pinpointing Alzheimer pathogenesis.

Mattsson N, Blennow K, Zetterberg H. Mattsson N, et al. Ann N Y Acad Sci. 2009 Oct;1180:28-35. doi: 10.1111/j.1749-6632.2009.04944.x. Ann N Y Acad Sci. 2009. PMID: 19906258 Review.

7

Converging molecular pathways in human neural development and degeneration.

Mattsson N, Sävman K, Osterlundh G, Blennow K, Zetterberg H. Mattsson N, et al. Neurosci Res. 2010 Mar;66(3):330-2. doi: 10.1016/j.neures.2009.11.012. Epub 2009 Dec 2. Neurosci Res. 2010. PMID: 19961883

8

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall.

Mattsson N, Blennow K, Zetterberg H. Mattsson N, et al. Clin Chem Lab Med. 2010 May;48(5):603-7. doi: 10.1515/CCLM.2010.131. Clin Chem Lab Med. 2010. PMID: 20201744 Review.

9

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.

Mattsson N, Zetterberg H, Blennow K. Mattsson N, et al. Int J Alzheimers Dis. 2010 Jul 8;2010:610613. doi: 10.4061/2010/610613. Int J Alzheimers Dis. 2010. PMID: 20721354 Free PMC article.

10

Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia.

Mattsson N, Rüetschi U, Pijnenburg YA, Blankenstein MA, Podust VN, Li S, Fagerberg I, Rosengren L, Blennow K, Zetterberg H. Mattsson N, et al. Mol Med Rep. 2008 Sep-Oct;1(5):757-61. doi: 10.3892/mmr_00000025. Mol Med Rep. 2008. PMID: 21479482

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

239 results

Search Page

Filters